Schlaganfallkonsortium Rhein-Neckar (Stroke Consortium Rhine-Neckar)
Launched by UNIVERSITY HOSPITAL HEIDELBERG · May 16, 2017
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
The FAST study is a clinical trial aimed at improving the care and outcomes for patients who have experienced an ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels supplying the brain. This trial is part of a larger network in Germany focused on stroke treatment. Researchers want to learn more about how many stroke patients need a special procedure called thrombectomy, which helps remove the blockage, and to find the best ways to provide this treatment quickly and effectively.
To participate in the trial, individuals must be 18 years or older and have been diagnosed with an ischemic stroke, and they need to provide informed consent, which means they understand and agree to take part in the study. Anyone who cannot give informed consent will not be eligible. Participants can expect to be part of a research effort that seeks to enhance stroke care, and they will be closely monitored by healthcare professionals throughout the process. This study is currently recruiting participants of all genders and aims to gather important information that could lead to better stroke treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • Patients with ischemic stroke who are admitted to one of the hospitals of the Stroke Consortium Rhein-Neckar (FAST)
- • informed consent
- Exclusion Criteria:
- • no informed consent
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Germany
Patients applied
Trial Officials
Wolfgang Wick, Prof. Dr.
Principal Investigator
University Hospital Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials